Assessing Patient Management and Outcomes in Atrial Fibrillation: Does your Health Insurance Plan know more than your Doctor?
作者信息
Saksena Sanjeev, Slee April
机构信息
Electrophysiology Research Foundation, Warren, New Jersey.
Department of Medicine Robert Wood Johnson Medical School, New Brunswick, New Jersey,c. Axio Research Corporation, Seattle, Washington.
出版信息
J Atr Fibrillation. 2009 Apr 1;1(6):181. doi: 10.4022/jafib.181. eCollection 2009 Apr-May.
Abstract
摘要
相似文献
1
Assessing Patient Management and Outcomes in Atrial Fibrillation: Does your Health Insurance Plan know more than your Doctor?评估心房颤动患者的管理与预后：你的健康保险计划比你的医生了解得更多吗？
J Atr Fibrillation. 2009 Apr 1;1(6):181. doi: 10.4022/jafib.181. eCollection 2009 Apr-May.
2
Information from your family doctor. Atrial fibrillation.来自你家庭医生的信息。心房颤动。
Am Fam Physician. 2002 Jul 15;66(2):271-2.
3
KNOW your Blue Shield plan.了解您的蓝盾保险计划。
Nebr State Med J. 1952 Dec;37(12):402.
4
Information from your family doctor. Atrial fibrillation.来自您家庭医生的信息。心房颤动。
Am Fam Physician. 2011 Jan 1;83(1):71-2.
5
What it means when your doctor says . . ."you have atrial fibrillation".当你的医生说……“你患有心房颤动”时意味着什么。
Harv Heart Lett. 2013 May;23(9):3.
7
Applying the atrial fibrillation guidelines update to manage your patients with atrial fibrillation.应用房颤指南更新内容来管理您的房颤患者。
Can J Cardiol. 2014 Oct;30(10):1241-4. doi: 10.1016/j.cjca.2014.05.022. Epub 2014 Jun 20.
8
Preparing your practice for any emergency scenario: your practice continuity plan.为你的诊所应对任何紧急情况做好准备：你的诊所连续性计划。
J Med Pract Manage. 2012 Jan-Feb;27(4):199-202.
9
Atrial fibrillation: the newest frontier in arrhythmia management.心房颤动：心律失常管理的最新前沿领域。
Prog Cardiovasc Nurs. 2002 Summer;17(3):110-23, 141. doi: 10.1111/j.0889-7204.2002.01450.x.
10
What you need to know about your dental plan.你需要了解的关于你的牙科保险计划的信息。
J Mich Dent Assoc. 2002 Aug;84(8):11.
本文引用的文献
1
Epidemiology and outcomes in patients with atrial fibrillation in the United States.美国心房颤动患者的流行病学及转归
Heart Rhythm. 2008 Oct;5(10):1365-72. doi: 10.1016/j.hrthm.2008.07.014. Epub 2008 Jul 17.
2
Challenges of establishing new antithrombotic therapies in atrial fibrillation.
Circulation. 2007 Jul 24;116(4):449-55. doi: 10.1161/CIRCULATIONAHA.107.695163.
3
The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation.新的医疗保险D部分处方药福利：对患有心房颤动的医疗保险人群处方药成本影响的估计
J Am Geriatr Soc. 2007 Jul;55(7):1038-43. doi: 10.1111/j.1532-5415.2007.01285.x.
4
Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation.欧洲心房颤动患者在临床表现、治疗及预后方面的性别差异：来自欧洲心房颤动心脏调查的报告
J Am Coll Cardiol. 2007 Feb 6;49(5):572-7. doi: 10.1016/j.jacc.2006.10.047. Epub 2007 Jan 22.
5
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).美国心脏病学会/美国心脏协会/欧洲心脏病学会2006年心房颤动患者管理指南——执行摘要：美国心脏病学会/美国心脏协会实践指南工作组及欧洲心脏病学会实践指南委员会（修订2001年心房颤动患者管理指南写作委员会）报告
J Am Coll Cardiol. 2006 Aug 15;48(4):854-906. doi: 10.1016/j.jacc.2006.07.009.
6
Antithrombotic therapy practices in US hospitals in an era of practice guidelines.实践指南时代美国医院的抗血栓治疗实践
Arch Intern Med. 2005 Jul 11;165(13):1458-64. doi: 10.1001/archinte.165.13.1458.
7
Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis.华法林抗凝治疗与心房颤动患者的预后：一项系统评价和荟萃分析。
Chest. 2004 Dec;126(6):1938-45. doi: 10.1378/chest.126.6.1938.
8
Atrial fibrillation as a contributing cause of death and Medicare hospitalization--United States, 1999.
MMWR Morb Mortal Wkly Rep. 2003 Feb 21;52(7):128, 130-1.
9
A comparison of rate control and rhythm control in patients with atrial fibrillation.心房颤动患者心率控制与节律控制的比较。
N Engl J Med. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328.
10
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.华法林治疗期间CYP2C9基因变异与抗凝相关结局的关联。
JAMA. 2002 Apr 3;287(13):1690-8. doi: 10.1001/jama.287.13.1690.
Zotero 插件